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 Surgical excision and laser are the two of the most commonly performed 
treatments for congenital melanocytic nevi, a type of birthmark present at birth or 
manifest infancy. Children with small to medium-sized congenital melanocytic nevi on 
the face and neck may elect treatment. However, there is no evidence-based guideline for 
the choice of treatment for small to medium-sized congenital melanocytic nevi that 
considers a child’s quality of life. We propose a non-randomized, open-label trial to 
compare the functional effect of surgical excision and laser treatment on the holistic 
wellbeing of school-aged children with head and neck congenital melanocytic nevi of 
≤10 cm. We will also use the Children’s Dermatology Life Quality Index to evaluate pre- 
and post-procedural health-related quality of life. This proposed study is the first to 
compare the two common treatments for congenital melanocytic nevi, which will 
contribute to the evidence-based guidance for clinical practice.  
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Chapter 1 Introduction 
1.1 Background 
Congenital melanocytic nevi (CMN) are benign proliferations of neural crest 
melanocytes present at birth or manifest within the first few weeks of life.119 A recently 
developed consensus-based standardized categorization scheme categorizes CMN into 
the following groups: small (<1.5 cm), medium (1.5-20 cm), large (>20-40 cm), and giant 
(>40 cm).70 Medium CMN is further categorized into two subgroups: M1(1.5-10 cm) and 
M2 (≤10 -20 cm). Treatments used for CMN include surgical excision, dermatome 
shaving, curettage, dermabrasion, chemical peels, cryotherapy, electrosurgery, radiation 
therapy, and different laser treatment modalities.54 However, to the best knowledge of the 
author, there is no current evidence-based guideline for the choice of treatment method 
for CMN. Treatment choices usually depend on the expertise and experience of the 
managing dermatologists and plastic surgeons, taking into consideration lesion size, 
location, and morphology; and ease of monitoring, cosmetic concerns, functional issues 
and anxiety of patients and their families.58,87,101,109 
Empirically, surgical excision is recommended as the first-line treatment for 
CMN when treatment is indicated, since it theoretically reduces the risk of melanoma by 
complete or partial removal of the nevomelanocytes.22,88,127  However, Arad and Zuker 
found no evidence that surgical treatment reduces melanoma risk in a recent literature 
review.8 Mann proposed that melanoma may still occur after surgical excision due to the 
existence of melanocytes in subcutaneous fat, fascia and muscle.84 Other studies found 
that a significant number of malignant melanoma arise outside the CMN and even the 
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skin.63,66 Excision of the CMN will not reduce the risk of extracutaneous melanoma or 
neurocutaneous melanosis.54,63  
Cosmetic outcome of surgery varies significantly across studies; surgical excision 
of small to medium-sized CMN usually result in better cosmetic outcome compared to 
large to giant CMN.54,71,109 A large prospective study has shown that even though not all 
the cosmetic results were satisfactory, families of children with small to medium-sized 
CMN generally found the surgical excision overall worthwhile.65 This was especially true 
for nevi on the head or neck; 95-96% families of the children with CMN on the head or 
neck deemed the surgical excision overall worthwhile. However, a follow-up study on the 
same population has shown that partial excision appeared to associate with less natural 
lightening of the original nevi and more development of new nevi over the years.63 It is 
proposed that surgical interventions activate melanocytes, even though this phenomenon 
has not been confirmed by other studies. In addition, serial excision and tissue expansion 
before surgical procedures are frequently required for CMN >5cm, which could be a 
process for months and may contribute to reduced quality of life in school-aged children 
due to multiple operations, frequent clinical visits, and the cosmetic deformity and 
discomfort during the expansion process.100 General risks of surgical interventions, 
including the risk of general anesthesia infection, bleeding, and post-operative 
impairment of functions, should also be factored in the general well-being of the 
children.11,88 Post-surgical scars can be disfiguring and even affect function.54 In some 
cases, there is also increased risk of distortion to adjacent structures.100 
Laser is another commonly used treatment method for CMN, usually serves as an 
option when surgical excision is not feasible.58,109 Laser treatment, usually if not always, 
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requires multiple sessions over months.54,88 Post-operative darkening, crusting, blistering 
of the nevi are common and may temporarily worsen the cosmetic appearance.9 Laser 
treatment often does not remove all nevomelanocytes, especially those in the deeper layer 
of the skin. Repigmentation after the procedure is common.69,121 Therefore, laser 
treatment is not a definitive treatment and the treated CMN will require life-long follow 
up.24 Woodrow and Burrows reported a case of malignant melanoma occurring at the 
periphery of a giant CMN previously treated with laser treatment.132 They voiced the 
concern for the potential malignant conversion of CMN induced by the laser treatment, 
even though giant CMN was known to associate with heightened risk of melanoma.128 
Some case series reported malignant melanoma occurrence after laser treatment, but none 
was originated from a CMN. In fact, multiple studies have looked at the long-term effect 
of laser treatment on CMN and found no other documented malignant changes induced 
by laser, even though the quality of evidence was low.38,46,56 Pseudomelanoma, a 
proliferative response to either laser or surgical excision was reported.53,72,120 However, it 
is decided to be a benign process and represents recurrence of CMN. It is safe to say that 
the effectiveness and safety of laser treatment is not thoroughly understood, which limits 
its utilization.  
Although laser treatment has a few drawbacks, it offers some unique advantages. 
Compared to surgical excision, laser treatment is less invasive and more selective. Post-
procedure scaring may be minimized compared to surgical excision.9,54,121 In older 
children and adults, laser treatment often requires only local anesthesia, which reduces 
potential anesthesia-related adverse events and side effects. Compared to surgical 
excision, laser treatment causes less irreversible changes to the skin. Patients with 
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unsatisfied laser treatment outcome can subsequently elect for surgical excision if 
appropriate. These may explain the finding in a recent study that for elective treatment to 
improve cosmetic outcome, most CMN patients (24/28) preferred laser treatment over 
surgery.10  
Laser modalities that are commonly used in CMN treatment include ablative 
lasers and pigment-specific lasers. Ablative lasers target water molecules and 
nonspecifically vaporize tissue, which may lead to more scaring theoretically.9 Pulse 
duration decides the amount of heat transmitted to the surrounding tissue; the longer the 
pulse duration, the high the chance of surrounding tissue injury and scar formation.117 
However, data have shown that scarring complication was more often seen in patients 
with large to giant CMN.38 Pigment-specific lasers have specific wave lengths that fall in 
the absorption range of melanin. It targets nevus cells with selective photothermolysis 
and theoretically cause less scaring.9 In a recent systemic review, Eggen and colleagues 
reported that combined ablative and Q-switched pigment-specific laser treatment 
achieves the best clearing of hyperpigmentation on both long and short term, with over 
90% patients reported good to excellent clearing, although the quality of the evidence 
was low.38 However, this study did not differentiate the types of ablative and pigment-
specific lasers. Theoretically, the ablative laser removes the epidermal nevus cells and 
facilitates the penetration of the pigment-specific laser by exposing the deep-seated 
nevomelanocytes.10,73,98 Two studies have reported that the addition of ablative laser to 
pigment-specific laser reduced the number of treatment sessions and shortens the 
therapeutic period needed for clearance of CMN.10,98 Data have shown that scarring was 
negligible with the use of pigment-specific lasers, since pigment-specific lasers targeted 
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melanocytes and caused little damage to the surround tissue.38 This suggests that the 
addition of pigment-specific laser to ablative laser may reduce scarring complication.  
CO2 laser is a type of ablative lasers. Q-switched Alexandrite laser (QSAL) is a 
type of pigment-specific laser. Both have been tested on CMN alone with good results. 
The combined CO2 and QSAL is a new modality of combined laser treatment that has 
been tested on CMN with fair results in the recent years. Three studies reported a total of 
41 patients who underwent combined CO2 and QSAL treatment (Table 1).
10,34,62 Of note, 
these three studies are all case series, offering limited strength of evidence to support the 





Melanoma prevention is a primary reason for children with CMN on head and 
neck and their families elect for treatment, primarily surgical excision.39,121  The risk of 
malignant change of CMN appears proportional to the size of the lesion; the risk of 
melanoma arising from small and medium-sized CMN is less than 1% over a 
lifetime.101,109 The low risk of malignant changes along with the new evidence 
aforementioned, that surgical excision may not reduce melanoma risk, may change the 
rationale of the treatment choices for CMN in children.  
Another primary reason for elective treatment for CMN is to diminish 
disfigurement associated with CMN.39 One underlying goal for appearance correction 
with elective treatment is to improve the children’s psychosocial wellbeing.112 However, 
traditional outcome measures, including cosmetic outcome, do not capture the full range 
of the impact of CMN and the interventions on the children.67 Health-related quality of 
life (HRQOL) is a progressively recognized measure to assess the broader effect of the 
health and psychosocial wellbeing of the children. In a recent case series, two out of four 
patients with mild CMN recurrence on nasal ala treated with laser were content to leave 
the recurrence as it was.135 This suggests that contrary to popular belief, the improvement 
of quality of life may not rely on the complete removal of the CMN. Managing and 
lightening the exposed CMN lesions with periodic laser therapies, instead of definite 
surgical excision, may lead to equal or possibly better outcome in quality of life.   
 
1.2 Statement of the Problem 
About 14% of CMN present on the head and neck.89 CMN on head and neck are 
highly visible and aesthetically important. Studies have shown that head and neck CMN 
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was associated with significant psychological sequelae.15,116 School-aged children with 
head and neck CMN are at higher risk of negative psychosocial experience. Previous 
studies have shown that school-aged children with head and neck CMN reported reduced 
HRQOL and increased perceived stigmatization, compared to younger children.90,91 
Many factors may contribute to this phenomenon. Firstly, appearance-related teasing is a 
common phenomenon in school. Adolescent with facial difference reported more 
perceived teasing than their peer without facial difference.41 In addition, school-aged 
children spend more time outside their familiar environment compared to younger 
children and are exposed to the reactions of strangers. Finally, school-aged children may 
be more aware of their condition compared to their younger counterpart.90 
School-aged children with head and neck CMN and their families may decide on 
elective procedures to improve the children’s cosmetic outcome and their quality of life. 
However, the effect of medical procedures on quality of life is not totally benign. Besides 
the risk of treatment failure and complication, treatment may have additional negative 
psychosocial effect on children with CMN. Some believe a scar is more socially 
acceptable than a congenital lesion.68 Krengel and Marghoob summarized that three out 
of four older children and adolescents preferred a surgical scar over the original nevus.69 
However, Patrick and colleagues discovered that adolescents with acquired facial lesions, 
such as burns, were more likely to report negative self-image and negative emotions than 
adolescents with congenital facial lesions, including facial CMN.99 Strauss and 
colleagues also reported that adolescents with acquired facial lesions experienced more 
staring from others, compared to those with congenital facial lesions.116 This suggests 
that scar-generating treatments may have a negative psychological impact on the 
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children, compared to no treatment. The true psychological effect of scar-generating 
procedures to remove existing head and neck CMN is unclear, and likely depends on the 
size and quality of both the original nevi and the scars. In addition, the process of 
treatment itself may affect children’s psychologic health. Small children dislike being 
restrained and older children become fearful and anxious due to the anticipation of pain 
associated with the procedures.112 The anticipation of medical procedures with the use of 
anesthesia may also generate anxiety in the children and their families. A recent study by 
Wramp and colleagues investigated the effect of the evolution of the nevi and prior 
treatment experience on the quality of life in children with CMN aged 4-16.39 However, it 
is difficult to isolate the effect of the treatment from the effect of the nevi since there was 
no comparison before and after the treatment.  
 
1.3 Goals  
To navigate the clinical decision on choosing elective treatment for head and neck 
CMN of ≤10 cm in school-aged children, this study aims to compare the functional 
effects of surgical excision and laser treatment on HRQOL in this population. Among 
school-aged children with head and neck CMN of ≤10 cm, we hypothesize that compared 
to the surgical group, there will be a statistically significantly greater improvement of 
HRQOL in the laser group, measured as the mean change of the Children’s Dermatology 
Life Quality Index, before and after the procedures in six months.  
We focus on small to M1 CMN (≤10 cm) because the majority of CMN are less 
than 3 to 4 cm; larger CMN are substantially rarer.6 The size of the CMN appears to 
correlate with the depth of nevomelanocytes; small to medium-sized CMN usually 
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present clinically and histologically similar.14 Although one may think that small CMN 
have minimal effect on children’s HRQOL, if the children and their families are 
concerned enough to elect for cosmetic procedures, the nevi and treatment choice likely 
will have an impact on children’s HRQOL. Other categories of CMN will not be 
included, such as M2, large and giant CMN (>10 cm) and multiple small to medium-
sized CMN.70 These lesions are likely to have a heightened malignant risk profile.6 In 
addition, due to the increased body surface area these larger CMN cover, their treatment 
generally requires special considerations and is a greater management challenge.8  
We will exclude CMN on the scalp and the posterior neck, because CMN on these 
locations may be covered by hair and are less visible. We will also exclude periorbital 
and periauricular CMN. CMN on these anatomical significant locations requires special 
treatment considerations to preserve organ function and improve cosmetic outcome, 
which has been described by many.16,20,33,37,52,57,78,83,133,134 Most head and neck CMN are 
on the front rather than on the back of head and neck.64 Periorbital and periauricular 
CMN are also very rare.37,136  
We will exclude CMN with empirically suspicious or concerning features that 
warrant excision. These clinically suspicious features are well delineated in the 
literature.88,109 Other variants of congenital or acquired melanocytic disorders are also 
excluded, such as nevi spilus, dysplastic nevi, blue nevi, Spitz nevi, café-au-lait macules 






This study is the first to compare the psychological effect of two major treatment 
choices for head and neck CMN, surgical excision and laser treatment. Instead of the 
cosmetic outcome of the treatments, this study will focus on the general psychological 
wellbeing of school-aged children, which can be a product of the cosmetic outcomes and 
the children’s and their families’ perception and tolerance of the treatments. The study 
result will provide a data-driven patient-centered guidance for the treatment choice of 
small to M1 CMN on head and neck in school-aged children. 
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Chapter 2 Literature Review 
2.1 Health-Related Quality of Life and its Assessment 
The definition of health-related quality of life (HRQOL) has continued to evolve 
since its introduction in 1970s. At least four definitions were reported in the literature.61 
The Centers for Disease Control and Prevention defines HRQOL as a broad concept that 
“encompass those aspects of overall quality of life that can be clearly shown to affect 
health—either physical or mental, which includes physical and mental health perceptions 
(e.g., energy level, mood) and their correlates—including health risks and conditions, 
functional status, social support, and socioeconomic status.”29  
Dermatological diseases often have a strong psychosocial and functional impact 
on the patients,2,43,122 and children are particularly vulnerable to the negative psychosocial 
impact caused by dermatological diseases.17,68,86,91,129 HRQOL synthesizes objective 
functional status and subjective perception of wellbeing in physical, mental, and social 
domains and focuses on their impacts on the perceptions of life satisfaction and quality,94 
therefore it is an all-inclusive measure to inform the degree of impairment, the need for 
treatments, and the effectiveness of interventions in pediatric patients with 
dermatological diseases.26,42,129 The European Academy of Dermatology and 
Venereology Task Force summarized a wide range of potential benefits of measuring 
HRQOL in dermatological practice, including to inform clinical decisions, promote 
clinician-patient communication, promote awareness of skin disease burden, inform 
consultation, and clinical service administration.44 For these benefits, life quality 
measures have rapidly gained interest in pediatric dermatology in recent years.44,47 As 
interest in HRQOL grew, an increased number of valid and reproducible HRQOL 
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instruments were developed in an attempt to better capture HRQOL specific to pediatric 
patients with dermatological conditions.26,30,31,40,60,76,77,114 
Children’s Dermatology Life Quality Index (CDLQI) is a standardized instrument 
to assess HRQOL among pediatric dermatological patients.76 Developed in 1995 by 
Lewis-Jones and Finlay, it was based on the result of an open-ended questionnaire among 
children aged 3‒16 years attending a pediatric dermatology clinic. The questionnaire 
identified 111 different aspects of life affected by the children’s dermatological 
conditions, which were sorted into different topics. From these topics the most identified 
aspects were elected to form the ten questions that constitute the CDLQI. These ten 
questions focus on children’s perception of the impact of their skin conditions on 
different aspects of their HRQOL in the past week, covering symptoms, emotions, 
friendship, clothes, social activities, physical activities, school work, perception of 
stigmatization, sleep, and treatment. Each question is scored on a four-point Likert scale 
to represent the impact of the skin condition on the children’s everyday life, with 0 being 
the least and 3 being the most impact. Children can achieve a CDLQI score of a 
minimum of 0 and a maximum of 30. Higher scores represent greater impairment of the 
children’s HRQOL.  
CDLQI is the first dermatology-specific quality of life measure specifically for 
children with skin disease, and was developed to parallel the Dermatology Life Quality 
Index (DLQI), the first dermatology-specific quality of life measure designed for adults.76 
CDLQI was validated among children aged 4‒16 years with dermatological conditions, 
including congenital melanocytic nevus (CMN). CDLQI is widely used and available in 
more than 50 languages.27,35,59,103,131 It was also expanded to include a cartoon version for 
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young patients.50 However, a significant drawback of CDLQI is that its self-reported 
nature does not allow for the measurement of objective functional status, even though it 
assesses self-reported functions. Some recent comments advocate that only perceived 
wellbeing, not functional assessment, should be used to determine quality of life because 
quality of life is inherently subjective.94 The lack of objective measures may be justified 
that the degree of impairment and the need for intervention will be perceived by the 
children and not by their doctors.   
Although CDLQI is a widely-used measure for patients with many pediatric 
dermatological diseases, its use in CMN research is limited. To our knowledge, only six 
studies have reported CDLQI scores among children with moles or nevi. The older terms 
moles and nevi are used in the past to refer to abnormal skin with increased melanocytes, 
which include CMN and other lesions with similar appearances.130 In the initial validation 
of CDLQI, Lewis-Jones and Finlay included 29 children with moles and reported CDLQI 
(SD) = 2.3 (2.9) in this sample.76 In the validation of the Cantonese version of CDLQI, 
Chuh reported CDLQI (SD) = 2.33 (2.08) in three children with moles and nevi.35 Beattie 
and colleagues look at CDLQI among 56 children aged 5-15 years with nevi, and 
reported CDLQI (SD) = 1.46 (3.04).17 In a study of the impact of cosmetic camouflage, 
Salsberg and colleagues reported CDLQI (SD) = 6.82 (1.28) in 22 children with various 
dermatological diseases; only one child had CMN.106 Another cosmetic camouflage study 
reported mean CDLQI = 5 among four children with nevi, without reporting SD.102 The 
most recent study reporting CDLQI scores among children with congenital nevi is by 
Wramp et al.; however, the reported data was aggregate and the mean was not reported.39  
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Besides the HRQOL measures in CDLQI, a few studies have focused on other 
significant predictors of HRQOL among children. Older age, female sex, and lower 
family socioeconomic status were found to be predictors of lower HRQOL among 
children and adolescents.48,85,97 A recent study in Netherland showed that the most 
significant determinants of HRQOL among general children aged 4-11 were the use of 
healthcare (including office visit, hospitalization, and medication) and the number of 
physical and mental disorders or complaints.51 A Dutch study also showed that chronic 
physical or mental conditions associate with lower HRQOL among school aged 
children.12 
 
2.2 Surgical Interventions and Laser Treatments Affect HRQOL 
Previously, few studies have looked at the relationship between treatment options 
and quality of life among children with head and neck CMN. The comparison of laser 
treatment and traditional surgery in other craniofacial disease entities may provide some 
insights for the treatment choices for head and neck CMN. A study compared 
postoperative HRQOL and pain among patients who underwent oral soft tissue surgery 
with either laser or cold blade.45 The result showed that laser group had significantly 
better HRQOL and lower postoperative pain compared with the surgery group. Another 
study also revealed better postoperative comfort for frenectomy patients with laser 
treatment compared to surgery.3 The advantage of laser treatment may be associated with 
the precise control of the depth and diameter of thermal injury. Compared to traditional 
surgeries, laser treatment induces less bleeding, minimal damage to the surrounding 
tissue, and reduced immediate postoperative pain due to nerve endings sealing by laser 
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irradiation.3 However, these advantages of laser treatment over surgical excision has not 
yet been tested among children with CMN.  
Among dermatological diseases, laser treatment was shown to improve HRQOL 
among patients with vitiligo4,107,137, port-wine stain110,113, atopic dermatitis13, rosacea118, 
and acne scars126. Laser treatment also reduced DLQI scores within one to two months 
postoperatively among women with facial hirsutism.82 However, long-term quality of life 
improvement was not found in this study. The short-term only quality of life 
improvement was likely associated with a high rate of reappearance of facial hirsutism. It 
may also imply that laser treatment has little immediate negative impact on patient’s 
quality of life, even given its potential side effects. Indeed, even though reappearance was 
very common, many patients were satisfied and willing to undergo further treatment. The 
quality of life improvement effect of laser treatment among women with facial hirsutism 
was replicated by a later study.92  
The immediate side effects of laser treatment were described in a prospective 
cohort study focusing on the effect of pulsed dye laser on port-wine stain.81 Tightness, 
soreness, and burning are common early post-operative complaints. Symptoms were 
resolved on the day of treatment in most patients. But in some the symptoms lasted a 
maximum of 3 days. Post-operative swelling, weeping, crusting, and bruising were also 
reported. These skin changes that may temporarily worsen the cosmetic appearance lasted 
up to 36 days. Post-operative purpura and hyperpigmentation were also reported among 
patients with atopic dermatitis treated with lasers.13  
An ongoing Swiss prospective cohort study (ClinicalTrials.gov Identifier: 
NCT02280889) seeks to understand how surgical excision of CMN affects children’s 
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quality of life. However, this study is in the recruitment phase and interim analysis is not 
yet available.123 The results from a systematic review suggested that facial cosmetic 
surgeries improve self-esteem and quality of life.55 However, the systematic review did 
not include cosmetic surgery for CMN or other skin diseases. Facial cosmetic surgeries 
reported to improve patients’ HRQOL include rhinoplasty,32,36,80,105,108,111 
otoplasty,19,23,93,115 facial palsies reconstruction,21,49,79 and orthodontic surgery.7  
Many factors may affect the HRQOL changes after facial cosmetic surgery. A 
prospective cohort study showed that the age of the patient, preoperative expectations, 
and the origin of the decision for surgery (particularly in adolescents) significantly affect 
post-operative psychosocial improvement.74 Sex may also confound the relationship 
between facial cosmetic surgery and HRQOL. Nicodemo and colleagues found that 
females have improved self-esteem and decreased depressive symptoms after 
orthognathic surgery, while males show no changes with surgery.95 
CMN is unique compared to other craniofacial defects, and CMN patients may 
have unique responses to surgical excision. Most facial cosmetic surgeries improve not 
only the cosmetic and psychosocial outcomes, but also physical functions. Though the 
skin of the nevus is often dry and prone to irritation and itching, CMN alone usually does 
not affect physical functions. Therefore, CMN patients may have less postoperative 
HRQOL improvement. Vivar and Kruse speculated that surgical excision may have little 
effect on self-esteem among children with CMN because the cosmetic outcome from 
surgical excision varies and is sometimes undesirable.125 Antoun and colleagues found 
that orthodontic surgery significantly improves physical pain, psychological discomfort, 
and psychological disability among malocclusion adolescents, but not among adolescents 
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with cleft lip and/or palate.7 It is believed that the prolonged management of a cleft lip 
and/or palate, the dissatisfaction with upper lip and nose after surgery, and the need for 
further surgery contribute to the less improvement of HRQOL among adolescents with 
cleft lip and/or palate. This implies that the response to surgical excision may also vary 
among CMN patients because the number of surgeries and the cosmetic outcome greatly 
depend on the location and morphology of the nevus.  
HRQOL improvement is more likely to be seen in 6 months than in 2 months 
after facial cosmetic surgeries, likely due to the immediate postoperative skin changes 
such as the healing wound, erythema, residual edema and bruising.55 There are also 
postoperative problems and complication associated with surgical excision of CMN, such 
as dressing changes, immobilization, failure to remove the entire lesion, impaired wound 
healing, dehiscence, and scar formation.39,54 
Surgery and laser treatment are inherently different procedures with different 
mechanisms. Both interventions are shown to improve HRQOL among patients with 
other diseases; for some diseases, laser treatment seems to result in more HRQOL 
improvement than surgery. As treatment options for CMN, surgical excision and laser 
treatment may affect the patient’s HRQOL in different ways. Compared to surgery, laser 
treatment is associated with less postoperative pain and faster healing. While temporary 
postoperative skin changes from laser treatment rarely last for more than one month, skin 
changes from surgery may last for more than two months. Postoperative skin changes 
including scarring may also be less prominent in laser patients since laser treatment tends 
to be less traumatic and invasive. As facial scaring has a negative social, emotional and 
functional impact on the patient,25,75 this choice of treatment may subsequently affect the 
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patient’s quality of life. Besides the immediate effects of the treatment, the potential 
differences between surgery and laser treatment that are clinically relevant include the 
cosmetic outcome, complications, negative emotion and stigmatization associated with 
the treatment, the time and the cost required by the treatment, and the number of clinical 
visits.18 As discussed in Chapter 1, the cosmetic outcome, complications and 
psychosocial response greatly vary among the two interventions. Laser treatment tends to 
require more clinical visits, and studies have shown that number of clinical visits is 
negatively associated with children’s HRQOL.51 Without existing studies comparing the 
two treatments and detailing how they affect HRQOL, the need for examining the 
different effect of surgery and laser treatment among school-aged children with head and 
neck CMN is significant. 
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Chapter 3 Study methods 
3.1 Study Design 
This international, multicenter, non-randomized, open-label clinical trial will 
recruit school-aged children (6-14 years) with congenital melanocytic nevus (CMN) of 
≤10 cm on head and neck who elect for cosmetic treatment. The study will be conducted 
by a consortium of clinical and research centers in the United States, Canada, Mexico, 
Europe and the Middle East. Physician and other healthcare professional members of the 
Pediatric Dermatology Research Alliance (PeDRA) will be invited to participate in this 
collaborative study. Protocol for this study will be submitted for review by the PeDRA 
Birthmarks group and the Institutional Review Board at each participating center.  
 
3.2 Study Population and Recruitment 
Eligible children will be referred to the study from their pediatricians, 
dermatologists, and/or plastic surgeons. We expect to enroll 128 children, with 64 
children in the surgical and laser group, respectively.  
 
3.2.1 Inclusion Criteria 
Patients must meet all following criteria to be enrolled in the study: 
1. Male or female who are 6-14 years of age at the time of screening. 
2. Patients must have a clinically documented diagnosis of single CMN on the head 
and neck which was present at birth or before the first birthday.1 
3. The CMN is ≤10 cm at largest diameter.  
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4. The CMN is completely or partially above the jugular notch, or completely or 
partially exposed when patient wears a crew-neck T-shirt.  
5. Patients must not have any previous surgical or dermatological treatment for 
CMN, including surgical excision, laser treatment, dermabrasion, curettage, and 
chemical peel. 
6. Patients must be currently enrolled in a primary school or middle school as full-
time students, who present to school five days per week during school terms. 
7. Patients and their caregivers must express a desire to improve cosmetic outcome 
via medical procedures. 
8. Patients and their caregivers must be able to provide concordant informed consent 
or assent. 
9. Patients must have public or private health insurance coverage. 
 
3.2.2 Exclusion Criteria  
Patients who meet the following criteria will be excluded from the study: 
1. Patients have CMN >10 cm or more than one small to medium-sized CMN on 
head and neck. 
2. Patients have CMN with spontaneous regression. 
3. The CMN has empirically suspicious or concerning features that may warrant 
excision,109 or the managing clinicians have medical concerns other than cosmetic 
consideration, such as malignant changes and post-procedural function loss. 
4. Patients have evidence or documented diagnosis of melanoma or 
symptomatic/complicated neurocutaneous melanosis. 
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5. Patients have Fitzpatrick skin type V or VI. As Alexandrite laser has been proven 
to be less safe in Fitzpatrick skin type VI.5  
6. Patients are unable to understand and follow instructions and complete the 
questionnaires with the help of an adult. 
7. Patients have a history of psychiatric or psychological disorders that could have 
an impact on either the interventions and the study outcomes. Examples include, 
but not limited to, body dysmorphic disorder and autism spectrum disorder.  
8. Patients have contraindications for surgery or laser treatment, including but not 
limited to coagulation disorders, immunodeficiency disorders, active infections, 
and photosensitivity disorders. 
9. Patients have any condition that, in the opinion of the investigators, may 
compromise the patient’s safety or compliance, preclude successful conduct of the 
study or interfere with interpretation of the results. 
 
3.3 Subject Protection and Confidentiality 
Patients and their legal guardians will be counselled regarding the risks, benefits 
and, alternatives of surgical excision and laser treatment. Written informed consent will 
be obtained prior to all procedures. All patients have the right to exit the study any time. 
All adverse events will be reported. In case of severe adverse events, the principle 
investigators and the physicians who perform the interventions will jointly decide 
whether to withdraw the patient from the study in a case-by-case basis.  
Patients and their legal guardians will be informed of the purpose of the study and 
assured of the confidentiality of the data. Research materials will be stored in locked 
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cabinets and shredded before discarding. Digital data will be stored and analyzed only on 
properly encrypted devices. All personal identifiable information will be deidentified 
prior to analysis to ensure confidentiality. Only the study investigators and their affiliated 
institutes will have access to the data set. Individual study participation will be entered 
into the patient’s Electronic Medical Record (EMR). Once placed in the patients’ EMR, 
these results are accessible to all providers who participate in the EMR system. 
Information within the EMR may also be shared with others who are appropriate to have 
access to the patient’s EMR (e.g. health insurance company, disability provider). 
 
3.4 Interventions 
After obtaining written informed consent at initial visit, pre-treatment CMN 
lesions will be measured and photographed. Eligible children and their families will be 
offered two treatment options, surgical excision and laser treatment. All procedures will 
be performed under general anesthesia. Children in the laser treatment group will have 
the option to undergo surgical excision one year after the last laser treatment session, if 
the children and the families elect to. 
 
3.4.1 Surgical Excision 
Patients in the surgical group will undergo one to two scheduled surgeries 
performed by plastic surgeons specialized in craniofacial reconstruction. The performing 
surgeon will independently evaluate the CMN and choose the surgical techniques suitable 
for the lesions. Techniques that are commonly used by craniofacial plastic surgeons for 
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CMN removal includes, but not limited to, excision with primary closure, serial excision, 
excision with flap reconstruction, and excision with skin graft.  
 
3.4.2 Laser Treatment  
Patients in the laser group will undergo a combined laser treatment modality that 
include carbon dioxide (CO2) laser and Q-switched Alexandrite laser, at six-week 
intervals for maximal six sessions. If optimal result is obtained before six sessions, the 
patient should return for each follow-up visit, but may choose to skip one or more 
sessions. Laser treatments will be performed by clinicians trained in laser treatments. 
During laser treatment session, the CMN will be first treated with a single pass or 
multiple passes of the CO2 laser with a pulse duration of one millisecond and a fluence of 
300 mJ/cm2. During ablation, carbonized tissue on the skin surface will be wiped off with 
a gauze soaked in normal saline. After the epidermis peels off, a further treatment will be 
followed with the single-pass Q-switched Alexandrite laser, with a pulse duration of 60 
nanoseconds, a fluence of 8 J/cm2, a spot size of 3mm2. 
 
3.5 Outcome and Covariates 
3.5.1 Primary Outcome 
The primary outcome is the change of health-related quality of life (HRQOL) 
before and six months after the last intervention, which will be assessed with the 
Children’s Dermatology Life Quality Index (CDLQI) questionnaire. A brief review of 




3.5.2 Secondary Outcomes 
The secondary outcomes are the changes of HRQOL one week and one month 
after each intervention. These secondary outcomes will also be measured by CDLQI.  
 
3.5.3 Other Covariates 
3.5.3.1 Sociodemographic Variables 
Patients’ age, sex, race, ethnicity, and household annual income per family 
member will be recorded in the initial study. Race includes Caucasian/White, African 
American/Black, Asian and Pacific Islander. Ethnicity includes Hispanic/Latino and non-
Hispanic/non-Latino.  
 
3.5.3.2 Other Dermatological Variables 
CMN morphologies (size, color, hair-bearing, flat or raised) and CMN locations 
(forehead, nose, cheeks, chin/jaw, and neck) will be described by the assessing 
dermatologists in the initial visit prior to any interventions. Post-procedural site color, 
size, healing status, repigmentation, and complications (pain, infection, hypertrophic 
scarring) will be assessed in each follow-up visit.  
Patients’ native skin color will be classified with Fitzpatrick skin phototype scale 




3.5.3.3 Other Health-Related Burdens  
To estimate other health-related burdens, we will also record other physical or 
mental comorbidities, annual healthcare visit frequency, number of healthcare visits last 
year, number of hospitalizations last year, current number of medications taken, maximal 
number of medication taken last year. Other physical or mental comorbidities will be 
listed out. To ascertain annual healthcare visit frequency, patients will be asked to choose 
from one of the four categories: never, sometimes, often, always. 
 
3.6 Data Collection and Statistical Considerations  
3.6.1 Data Collection  
Data will be collected via CDLQI questionnaires, sociodemographic surveys, 
physician’s notes and digital photographs. A baseline CDLQI questionnaire will be 
administered at the initial visit, before any intervention. Patients should complete the 
CDLQI questionnaires independently; caregivers may clarify the wording of the 
questions but should not answer the questions for the patients. Sociodemographic data 
and covariates will also be collected at the initial visit in a written survey; caregivers may 
answer this survey with the patients. Post-procedure CDLQI questionnaire will be 
administered at one week and one month after each procedure, and six months after the 
last procedure. This will allow us to investigate both the short term and long term effect 
of the treatment. CMN and post-procedural site characteristics will be abstracted from 
physician’s notes in each visit. Clinical photographs of CMN will be taken at all visits 




3.6.2 Sample Size Calculation  
In the existing literature, reported CDLQI scores among children with CMN range 
from 2.30 to 6.82, with the standard deviation (SD) ranges from 2.08 to 3.04.17,35,76,102,106 
As mentioned previously in Chapter 2, the reported data do not differentiate CMN with 
other lesions with similar morphologies, which may cause the SD of CDLQI scores in the 
samples to be overestimated. However, to be even more conservative, we assume a SD 
for CDLQI score among children with CMN to be 4. We also assume a mean difference 
of CDLQI scores in the laser group is 2 points higher than in the surgery group, because 
half a SD has been shown to be the smallest detectable difference for changes in HRQOL 
for chronic diseases.96 With a SD of 4 and a mean difference of 2, we will need to study 
64 children in each group (128 children in total) to be able to reject the null hypothesis 
that the population means of the surgery and laser groups are not significantly different 
with the power of 80% and the Type I error probability 0.05.  
No previous study has reported attrition data in this population. We expect low 
attrition due to the nature of the elective cosmetic procedures. Children and their families 
are expected to be highly motivated, especially when they are concerned enough to 
request consultation for nevus removal. In addition, prior to each visit, researchers will 




3.6.3 Data Analysis  
Descriptive statistics will be used to summarize patient demographic and CMN 
characteristics. Student’s t test will be used to compare the distribution of the primary and 
secondary outcomes in the surgical group and the laser group. Multiple linear regression 
model will be used to control for confounding. We will report 2-sided p-value. A p-value 
of < 0.05 is considered statistically significant. 
 
3.7 Timeline  
The study consists of two logistic phases: Phase 1 is recruitment and data 
collection and Phase 2 is data analysis. Phase 1 is planned to complete in two years 
(Figure 1). The first six months is subject recruitment. Surgeries and laser treatments can 
start as soon as patients qualify and consent for the study. The last intervention procedure 
of any patient should conclude six months prior to the end of Phase 1, allowing the six-
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Chapter 4 Discussion 
4.1 Advantages and Disadvantages 
Congenital melanocytic nevus (CMN) treatment may help to mitigate the negative 
impact of exposed CMN on a patient’s general wellbeing and health-related quality of 
life (HRQOL); yet, it is unknown how the choice of treatment affects a patient’s 
HRQOL. Due to the complexity of how CMN is affecting this population, school-aged 
children are of particular concern. It is essential that we provide evidence-based 
recommendations to children and their families who seek CMN treatment. However, few 
studies have focused on how treatment affect the general wellbeing among school-aged 
children with head and neck CMN. No previous study has directly compared the 
functional effect of surgical excision and laser therapy, the two common treatment 
choices for CMN. Our study is designed to address this gap in knowledge using a reliable 
and valid HRQOL measurement instrument. With the result of this study, we will 
determine the choice of treatment to achieve a better HRQOL effect among school-aged 
children with small to M1 CMN of the head and neck. As Children’s Dermatology Life 
Quality Index (CDLQI) covers different HRQOL domains, we may also learn more 
details about how the treatments are affecting HRQOL among this clinically important 
population. 
This study has several limitations. First, school-aged children who have health 
insurance coverage and have access to pediatricians and other healthcare specialists may 
be psychosocially different from their counterpart and have a different response to the 
interventions. However, we decided against expanding the sample due to the high cost of 
interventions. Second, a double-blind, randomized controlled trial is the best study design 
37 
 
for a treatment question. However, given the interventions are elective procedures, 
randomizing the children to a certain intervention group, regardless of the preference of 
the patients and the families, would be difficult, would likely hinder enrollment and 
increase attrition. The procedural differences between laser treatment and surgical 
excision prevent the blinding of the patients, their families and the investigators. A non-
randomized open-label trial inevitably has increased risk of bias; including selection, 
reporting and performance biases. Third, the standard deviation (SD) we used for sample 
size calculation may not be an accurate reflection of the SD among the true study 
population. The SD of CDLQI scores among the study population was extracted from six 
previous studies that reported CDLQI scores among children with moles or nevi. 
However, it is unclear whether the participants had CMN or other melanocytic lesions, 
such as acquired melanocytic nevi and lentigines, in some of the six studies. The location 
and the size of the lesions were also not reported in most studies. The SD estimate greatly 
influenced the sample size calculation, not only because it was a part of the sample size 
formula, but also because it was used to derive the minimally detectable effect size, 
which also affect the sample size calculation. However, there is no better-quality study in 
the literature to provide us with a more accurate SD estimate. In order to provide 
sufficient power to detect a small effect difference between laser treatment and surgical 
excision, we conservatively calculate the sample size with a larger SD estimate than the 




4.2 Clinical Significance 
Previous studies have mainly focused on the cosmetic outcome of treatment 
options; few studies have looked at the relationship between treatment options and 
quality of life among children with CMN. To our knowledge, this proposed study is the 
first study that attempts to compare the effect of two common treatment options on 
HRQOL among school-aged children with head and neck CMN of ≤10 cm. HRQOL 
captures patient’s perspectives of disease and treatment, their perceived need for health 
care, and their preferences for treatment and outcomes.28 Using HRQOL rather than 
solely relying on physical outcome reflects a growing appreciation of patient-centered 
care in the medical field.124 This study will re-examine the choice of treatment plan for 
school-aged children with small to medium-sized head and neck CMN. It will also inform 
clinicians, patients, and families, contribute to future evidence-based guidelines and 
improve decision-making in clinical practice. 
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Appendix I Sample Parental Consent Form  
 
PARENTAL CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL 
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL: SAINT RAPHAEL 
CAMPUS 
 
Study Title: COMPARING CONGENITAL MELANOCYTIC NEVUS TREATMENT 
EFFECT on CHILDREN’S HEALTH-RELATED QUALITY of LIFE 
Principal Investigator: Yunru Lai, PA-III, Richard Antaya, MD 
Funding Source: Pending 
 
Invitation to Participate and Description of Project 
Your child is invited to participate in a research study designed to look at the 
effect of different treatments on health-related quality of life among school-aged children 
with head and neck congenital melanocytic nevi. Congenital melanocytic nevi are 
birthmarks that you may notice at birth or in early infancy. Health-related quality of life 
measures a person’s general wellbeing related to health and diseases. Your child has been 
asked to participate because s/he is a full-time student between 6‒14 years, have one or 
more congenital melanocytic nevi on head and neck, and seek treatments. We expect to 
enroll 128 children in total across all study sites. 
In order to decide whether or not you wish your child to be a part of this research 
study you should know enough about its risks and benefits to make an informed decision.  
This consent form gives you detailed information about the research study, which a 
member of the research team will discuss with you.  This discussion should go over all 
aspects of this research: its purpose, the procedures that will be performed, any risks of 
the procedures, possible benefits and possible alternative treatments. Once you 
understand the study, you will be asked if you wish your child to participate; if so, you 
will be asked to sign this form. Your child will also be asked to sign an assent form if 







Description of Procedures 
When your child comes to the initial visit, s/he will fill out a form with your 
assistance for us to better know her/him. We will measure and photograph your child’s 
birthmark.  
If your child is deemed eligible, you may choose one from the two treatment 
options offered. The two treatment options include surgery and laser. All procedures will 
be performed under general anesthesia. 
If you choose surgery, your child will receive one (1) to two (2) scheduled 
surgeries performed by plastic surgeons specialized in craniofacial reconstruction. Your 
child’s surgeons will independently evaluate the birthmark and choose the surgical 
techniques suitable for her/his birthmark. Techniques that are commonly used by 
craniofacial plastic surgeons for the removal of this type of birthmark includes but not 
limits to excision with primary closure, serial excision, excision with flap reconstruction, 
and excision with skin graft.  
If you choose laser, your child will receive a maximum of six (6) monthly 
combined laser treatment sessions. All laser sessions are performed by clinicians trained 
in laser treatments. You and your child may choose to skip one or more sessions if 
satisfied result is obtained. However, your child should still return for each scheduled 
follow-up visit. The laser used in each session include CO2 laser and Q-switched 
Alexandrite laser. Your child will have the option to have surgeries after the trial, if you 
wish to. 
Regardless of the treatment chosen, your child will return for follow-up in one (1) 
week, one (1) month, and six (6) months after each treatment session. If your child is in 
the laser group, s/he may schedule her/his follow-up for the previous treatment session 
and the new treatment session in the same visit. 
In each treatment and follow-up session, the site of the birthmark will be assessed 
by a physician. Your child will be asked to independently complete a Children’s 
Dermatology Life Quality Index questionnaire. This questionnaire consists of 10 
questions about different aspects of her/his life in the past week. You may read the 
questions to your child and clarify words, but you child should be the one who answers 
all the questions without prompts.  
All treatments will be completed roughly in a year from the first treatment 
session. All data collection will be completed roughly in 18 months from the first 
treatment session. 
 
Risks and Inconveniences  
Surgical operations including laser treatment all involve RISKS OF 
COMPLICATIONS, SERIOUS INJURY, OR DEATH, from both known and unknown 
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causes. Potential complications of surgeries include pain, bleeding, infection, scarring, 
unsatisfactory results including incomplete removal of the nevus (birthmark), and injury 
to the nearby structures. Potential complications of laser surgeries include skin irritation 
including redness, swelling, itching, blistering, pain; change in skin color; unsatisfactory 
results including repigmentation (birthmark initially lightens but darkens over time); 
burns; scarring; and infection.  
General anesthesia also carries its own risks; potential complications associated 
with the administration of anesthetic drugs include, but not limit to, drowsiness, nausea, 
vomiting, pain, hematoma, phlebitis, numbness, swelling, bleeding, bruising, allergic 
reaction and death.  
 
Benefits 
Potential benefits from treatments include improvement of cosmetic outcome, 
improvement of psychosocial wellbeing, and reduction of cancer risk. 
  
Economic Considerations 
The cost of treatment involves several charges, including fees charged by the 
physician, the cost of pre- and post-operative skin care medications, surgical supplies, 
laboratory tests, possible hospital charges, and assisting personnel if applicable, 
depending on the type of procedure performed. Additional costs may occur should 
complications develop from the treatment.  
Your child’s health insurance plan will likely partially or completely cover 
congenital melanocytic nevus removal surgery and laser treatment, because it involves 
removal of a potentially cancerous lesion with or without the reconstruction of the area. 
You may be responsible for the copayment and/or deductible, per your child’s health 
insurance plan. In the rare case that your child’s health insurance plan does not cover the 
procedures, you will be responsible for the full payment. Discounts may be applicable on 
a case by case basis.  
 
Treatment Alternatives/Alternatives 
The most common treatment alternatives to having surgeries or laser treatments 
include curettage, dermabrasion, and chemical peels. Observation without interventions 







Research materials will be stored in locked cabinets and shredded before 
discarding. Digital data will be stored and analyzed only on properly encrypted devices. 
All identifiable information will be deidentified prior to analysis to ensure confidentiality. 
When the results of the research are published or discussed in conferences, no 
information will be included that would reveal your child’s identity unless your specific 
consent for this activity is obtained. 
Information about your child’s study participation will be entered into her/his 
Electronic Medical Record (EMR). Once placed in your EMR, these results are 
accessible to all of the providers who participate in the EMR system. Information within 
your child’s EMR may also be shared with others who are appropriate to have access to 
her/his EMR (e.g. health insurance company, disability provider.)  
Representatives from the Yale Human Research Protection Program, the Yale 
Human Investigation Committee (the committee that reviews, approves, and monitors 
research on human subjects) may inspect study records during internal auditing 
procedures. However, these individuals are required to keep all information confidential.  
 
Voluntary Participation and Withdrawal 
Participating in this study is voluntary. You are free to refuse your child’s 
participation in this study. Refusing to participate will involve no penalty or loss of 
benefits to which your child is otherwise entitled (such as your child’s health care outside 
the study, the payment for your child’s health care, and your child’s health care benefits).  
However, your child will not be able to enroll in this research study and will not receive 
study procedures as a study participant if you do not allow the use of your child’s 
information as part of this study. 
If your child does become a subject, your child is free to stop and withdraw from 
this study at any time during its course. To withdraw from the study, you can call a 
member of the research team at any time and tell them that you no longer want to take 
part.  This will cancel any future appointments.  
The researchers may withdraw your child from participating in the research if 
necessary. Conditions under which a subject might be withdrawn from the research 
include, but not limit to, when the subject is no longer a suitable candidate for a treatment 
plan due to health, the subject develops serious side effects or complications, or the 
subject is unable to comply to treatments or follow-up visits.  
Withdrawing from the study will involve no penalty or loss of benefits to which 
your child is otherwise entitled.  It will not harm your child’s relationship with her/his 
own doctors or with the affiliated institute including Yale-New Haven Hospital. 
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When you withdraw your child from the study, no new health information 
identifying your child will be gathered after that date.  Information that has already been 
gathered may still be used and given to others until the end of the research study, as 
necessary to insure the integrity of the study and/or study oversight.   
 
Questions 
We have used some technical terms in this form.  Please feel free to ask about 
anything you don't understand and to consider this research and the consent form 
carefully—as long as you feel is necessary—before you make a decision. 
 
Parent/legal guardian Authorization 
I, the parent or legal guardian, have read (or someone has read to me) this form 
and have decided for my child to participate in the project described above. Its general 
purposes, the particulars of my child’s involvement and possible hazards and 
inconveniences have been explained to my satisfaction. My signature also indicates that I 
have received a copy of this consent form. 
 
Name: ________________________ Signature: ________________________ 
 





Signature of Principal Investigator    Date 
  
                                      or 
 
___________________________________________ ___________________ 




If you have further questions about this project or if you have a research-related problem, you 
may contact the Principal Investigator (Yunru Lai, 937-344-8842).   
If, after you have signed this form you have any questions about your privacy rights, please 
contact the Yale Privacy Officer at 203-432-5919. If you would like to talk with someone other 
than the researchers to discuss problems, concerns, and questions you may have concerning this 
research, or to discuss your rights as a research subject, you may contact the Yale Human 
Investigation Committee at (203) 785-4688.  
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Appendix II Sample Consent Form  
 
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
For ages 13-14 years 
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL 
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL: SAINT RAPHAEL 
CAMPUS 
 
Study Title: COMPARING CONGENITAL MELANOCYTIC NEVUS TREATMENT 
EFFECT on CHILDREN’S HEALTH-RELATED QUALITY of LIFE 
Principal Investigator: Yunru Lai, PA-III, Richard Antaya, MD 
Funding Source: Pending 
 
Invitation to Participate and Description of Project 
You are invited to participate in a research study designed to look at the effect of 
different treatments on health-related quality of life among school-aged children with 
head and neck congenital melanocytic nevi. Congenital melanocytic nevi are birthmarks 
that you may notice at birth or in early infancy. Health-related quality of life measures a 
person’s general wellbeing related to health and diseases. You have been asked to 
participate because you are a full-time student between 6‒14 years, have one or more 
congenital melanocytic nevi on head and neck, and seek treatments. We expect to enroll 
128 children in total across all study sites. 
In order to decide whether or not you wish to be a part of this research study you 
should know enough about its risks and benefits to make an informed decision. This 
consent form gives you detailed information about the research study, which a member of 
the research team will discuss with you. This discussion should go over all aspects of this 
research: its purpose, the procedures that will be performed, any risks of the procedures, 
possible benefits and possible alternative treatments. Once you understand the study, you 
will be asked if you wish to participate; if so, you will be asked to sign this form. Your 
legal guardian(s) will also be asked to sign a consent form to give permission to your 
participation in this study. 
 
Description of Procedures 
When you come to the initial visit, you will fill out a form for us to better know 




If you are deemed eligible, you may choose one from the two treatment options 
offered. The two treatment options include surgery and laser. All procedures will be 
performed under general anesthesia. 
If you choose surgery, you will receive one (1) to two (2) scheduled surgeries 
performed by plastic surgeons specialized in craniofacial reconstruction. Your surgeons 
will independently evaluate the birthmark and choose the surgical techniques suitable for 
her/his birthmark. Techniques that are commonly used by craniofacial plastic surgeons 
for the removal of this type of birthmark includes but not limits to excision with primary 
closure, serial excision, excision with flap reconstruction, and excision with skin graft.  
If you choose laser, you will receive a maximum of six (6) monthly combined 
laser treatment sessions. All laser sessions are performed by clinicians trained in laser 
treatments. You may choose to skip one or more sessions if satisfied result is obtained. 
However, you should still return for each scheduled follow-up visit. The laser used in 
each session include CO2 laser and Q-switched Alexandrite laser. You will have the 
option to have surgeries after the trial, if you wish to. 
Regardless of the treatment chosen, you will return for follow-up in one (1) week, 
one (1) month, and six (6) months after each treatment session. If you are in the laser 
group, you may schedule your follow-up for the previous treatment session and the new 
treatment session in the same visit. 
In each treatment and follow-up session, the site of the birthmark will be assessed 
by a physician. You will be asked to independently complete a Children’s Dermatology 
Life Quality Index questionnaire. This questionnaire consists of 10 questions about 
different aspects of your life in the past week.  
All treatments will be completed roughly in a year from the first treatment 
session. All data collection will be completed roughly in 18 months from the first 
treatment session. 
 
Risks and Inconveniences  
Surgical operations including laser treatment all involve RISKS OF 
COMPLICATIONS, SERIOUS INJURY, OR DEATH, from both known and unknown 
causes. Potential complications of surgeries include pain, bleeding, infection, scarring, 
unsatisfactory results including incomplete removal of the nevus (birthmark), and injury 
to the nearby structures. Potential complications of laser surgeries include skin irritation 
including redness, swelling, itching, blistering, pain; change in skin color; unsatisfactory 
results including repigmentation (birthmark initially lightens but darkens over time); 
burns; scarring; and infection.  
General anesthesia also carries its own risks; potential complications associated 
with the administration of anesthetic drugs include, but not limit to, drowsiness, nausea, 
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vomiting, pain, hematoma, phlebitis, numbness, swelling, bleeding, bruising, allergic 
reaction and death.  
 
Benefits 
Potential benefits from treatments include improvement of cosmetic outcome, 
improvement of psychosocial wellbeing, and reduction of cancer risk. 
  
Economic Considerations 
The cost of treatment involves several charges, including fees charged by the 
physician, the cost of pre- and post-operative skin care medications, surgical supplies, 
laboratory tests, possible hospital charges, and assisting personnel if applicable, 
depending on the type of procedure performed. Additional costs may occur should 
complications develop from the treatment.  
Your health insurance plan will likely partially or completely cover congenital 
melanocytic nevus removal surgery and laser treatment, because it involves removal of a 
potentially cancerous lesion with or without the reconstruction of the area. You may be 
responsible for the copayment and/or deductible, per your health insurance plan. In the 
rare case that your health insurance plan does not cover the procedures, you will be 
responsible for the full payment. Discounts may be applicable on a case-by-case basis.  
 
Treatment Alternatives/Alternatives 
The most common treatment alternatives to having surgeries or laser treatments 
include curettage, dermabrasion, and chemical peels. Observation without interventions 
and cosmetic camouflage are common non-treatment alternatives.   
 
Confidentiality 
Research materials will be stored in locked cabinets and shredded before 
discarding. Digital data will be stored and analyzed only on properly encrypted devices. 
All identifiable information will be deidentified prior to analysis to ensure confidentiality. 
When the results of the research are published or discussed in conferences, no 
information will be included that would reveal your identity unless your specific consent 
for this activity is obtained. 
Information about your study participation will be entered into your Electronic 
Medical Record (EMR). Once placed in your EMR, these results are accessible to all of 
your providers who participate in the EMR system. Information within your EMR may 
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also be shared with others who are appropriate to have access to your EMR (e.g. health 
insurance company, disability provider.)  
Representatives from the Yale Human Research Protection Program, the Yale 
Human Investigation Committee (the committee that reviews, approves, and monitors 
research on human subjects) may inspect study records during internal auditing 
procedures. However, these individuals are required to keep all information confidential.  
 
Voluntary Participation and Withdrawal 
Participating in this study is voluntary. You are free to refuse to participate in this 
study. Refusing to participate will involve no penalty or loss of benefits to which you are 
otherwise entitled (such as your health care outside the study, the payment for your health 
care, and your health care benefits).  However, you will not be able to enroll in this 
research study and will not receive study procedures as a study participant if you do not 
allow the use of your information as part of this study. 
If you do become a subject, you are free to stop and withdraw from this study at 
any time during its course. To withdraw from the study, you can call a member of the 
research team at any time and tell them that you no longer want to take part.  This will 
cancel any future appointments.  
The researchers may withdraw you from participating in the research if necessary. 
Conditions under which a subject might be withdrawn from the research include, but not 
limit to, when the subject is no longer a suitable candidate for a treatment plan due to 
health, the subject develops serious side effects or complications, or the subject is unable 
to comply to treatments or follow-up visits.  
Withdrawing from the study will involve no penalty or loss of benefits to which 
you are otherwise entitled.  It will not harm your relationship with your own doctors or 
with the affiliated institute including Yale-New Haven Hospital. 
When you withdraw from the study, no new health information identifying you 
will be gathered after that date.  Information that has already been gathered may still be 
used and given to others until the end of the research study, as necessary to insure the 
integrity of the study and/or study oversight.   
 
Questions 
We have used some technical terms in this form.  Please feel free to ask about 
anything you don't understand and to consider this research and the consent form 




Patient Authorization (For children ages 13-14 years) 
I, _____________, have read (or someone has read to me) this form and have 
decided to participate in the project described above. Its general purposes, the particulars 
of my involvement and possible hazards and inconveniences have been explained to my 
satisfaction. My signature also indicates that I have received a copy of this consent form. 
 
Signature: ________________________   Date: ________________ 
 
Parent/legal guardian Authorization 
I, the parent or legal guardian, have read (or someone has read to me) this form 
and have decided for my child to participate in the project described above. Its general 
purposes, the particulars of my child’s involvement and possible hazards and 
inconveniences have been explained to my satisfaction. My signature also indicates that I 
have received a copy of this consent form. 
 
Name: ________________________ Signature: ________________________ 
 





Signature of Principal Investigator    Date 
  
                                      or 
 
___________________________________________ ___________________ 
Signature of Person Obtaining Consent   Date 
 
If you have further questions about this project or if you have a research-related problem, you 
may contact the Principal Investigator (Yunru Lai, 937-344-8842).   
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If, after you have signed this form you have any questions about your privacy rights, please 
contact the Yale Privacy Officer at 203-432-5919. If you would like to talk with someone other 
than the researchers to discuss problems, concerns, and questions you may have concerning this 
research, or to discuss your rights as a research subject, you may contact the Yale Human 
Investigation Committee at (203) 785-4688.  
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Appendix III Sample Child Assent Form 
 
CHILD ASSENT FORM 
for ages 7-12 years 
(To be read aloud to child) 
My name is _____________ (identify yourself to the child by name). I am doing a study 
trying to learn more about which birthmark treatment makes children feel better. The two 
treatments we are comparing are surgeries and laser. By agreeing to be in this study, you 
may be helping other kids who also have birthmarks choose the treatment that works 
better for them.  
If you agree to help us, you will be asked to come to the clinic for treatments and answer 
some questions to tell us how you feel. There are no right or wrong answers. If there is a 
question you don’t want to answer, just leave it blank. 
If you agree to help us, we will keep all your answers private, and will not show them to 
your classmates and teachers. Only people from Yale University working on the study 
will see them.   
Please talk this over with your parents before you decide if you want to be in my study or 
not. You should know that you do not have to be in this study if you do not want to. You 
won’t get into any trouble if you say no. I will also ask your parents to give their 
permission for you to be in this study, but even if your parents say “yes,” you can still say 
“no” and decide not to be in the study. You may also stop being in the study after we 
begin, that’s okay, too. 
You can ask any questions you have, now or later.  If you think of a question later, you or 
your parents can call me at _____________ (phone number). 
Sign this form or Answer “Yes” only if you: 
• have understood what you will be doing for this study, 
• have had all your questions answered, 
• have talked to your parent(s)/legal guardian about this project, and 
• agree to take part in this research 
 _______________________________________________________________________ 
Your Signature    Printed Name    Date 
_______________________________________________________________________ 
Signature of Assenting Researcher      Date 




Appendix IV Sample Sociodemographic Survey  
 
SOCIODEMOGRAPHIC SURVEY 
(To be completed by child, with the assistance of parents/caregivers) 
Name: ________________________  Date of Birth: __ / __ / ____ 
 
Education level & Grade:  
 Elementary school: _____________________________   
 Middle school: ________________________________ 
 Home schooling: ______________________________ 
 Others: ______________________________________ 
 
Sex:  
Male      Female 
 
Race: 
 Caucasian/White      African American/Black  
 Asian and Pacific Islander    Native Americans and Alaska Natives 
 Others: _________________________ 
 
Ethnicity: 
Hispanic/Latino    Non-Hispanic/non-Latino 
 
Household Annual Income: _________________________ 
 Less than $25,000     $25,000 to $49,999 
 $50,000 to $99,999    $100,000 or more 
 




Appendix V Sample Health-Related Burdens Survey 
 
HEALTH-RELATED BURDENS SURVEY 
(To be completed by child, with the assistance of parents/caregivers) 
Today’s Date: _______________ 
Today’s visit:  
 Initial visit      One-week follow-up 
 One-month follow-up    Six-month post-intervention follow-up 
 
Doctor’s visits: 
How often have you visited the doctor’s office in the past year?  
 Always      Often    
 Sometimes      Never 
 
How many times have you been hospitalized for in the past year? _________________ 
How many days have you been hospitalized for in the past year? __________________ 
 
Medications: 
How many different medications are you routinely taking currently? _______________ 
What is the maximal number of different medications you have routinely taken in the 
past year? ______________________________________________________________ 
 
Co-morbidities:  
List all the diagnosis of physical conditions you have had: 
________________________________________________________________________ 
________________________________________________________________________ 






Appendix VI Sample Lesion Characteristics Report 
 
LESION CHARACTERISTIC REPORT 
(To be completed by clinician) 
Today’s Date: _______________ 
Today’s visit:  
 Initial visit      One-week follow-up 
 One-month follow-up    Six-month post-intervention follow-up 
 
Complete only in initial visit: 
Fitzpatrick Skin Phototype: 
 I     II     III 
 IV     V     VI 
 
Complete in all visits: 
Lesion Location (choose all that apply): 
 Central (vertical area in-between outer canthi)   Lateral 
 Forehead    Nose    Cheeks  
 Chin/Jaw    Neck    Others: _______________ 
 
Lesion Size (cm × cm): ____________________________ 
 
Lesion Colors (choose all that apply):  
 Uniform    Multicolored 
 Skin-colored   Tan     Brown 
 Black     Purple    Pink  





Morphologies (choose all that apply): 
 Uniform    Irregular    Ulcerated 
 Flat     Raised    Hairless    
 Mildly hair-bearing  Moderately hair-bearing  Dense hair-bearing  
 N/A (s/p surgical excision) 
 
Complete only in follow-up visits: 
Pigmentation Clearance: 
 0-24%    25-49%    50-74%  
 75-100% 
 
Wound Healing Impression (choose all that apply): 
 Normal healing       Delayed healing 
 Abnormal surrounding skin color     Well-defined Edges 
 Undermining   Exudate    Induration 
 
Wound Bed Tissue Type: 
 Closed wound   Epithelial    Granulation  
 Slough    Necrosis 
 
Complications (choose all that apply): 
 Infection    Bleeding    Hypertrophic scar 
 Hyperpigmentation      Hypopigmentation   
 Others: ______________________________________ 
 
Pain: __________ / 10  




Appendix VII Sample Children’s Dermatology Life Quality Index Questionnaire 
 
 
CHILDREN'S DERMATOLOGY LIFE QUALITY INDEX 
(To be completed independently by child) 
Name:     Age:    CDLQI SCORE: 
 
Address:    Date:  
 
 
The aim of this questionnaire is to measure how much your skin problem has 
affected you OVER THE LAST WEEK.  Please tick ✓ one box for each question. 
 
 
1. Over the last week, how itchy, "scratchy",  Very much  □ 
 sore or painful has your skin been?   Quite a lot  □ 
Only a little  □ 
Not at all  □ 
 
2. Over the last week, how embarrassed  Very much  □ 
 or self conscious, upset or sad have you  Quite a lot  □ 
 been because of your skin?    Only a little  □ 
Not at all  □ 
 
3. Over the last week, how much has your  Very much  □ 
 skin affected your friendships?   Quite a lot  □ 
Only a little  □ 
Not at all  □ 
 
4. Over the last week, how much have you  Very much  □ 
 changed or worn different or special   Quite a lot  □ 
 clothes/shoes because of your skin?   Only a little  □ 





5. Over the last week, how much has your  Very much  □ 
 skin trouble affected going out, playing,  Quite a lot  □ 
 or doing hobbies?     Only a little  □ 
Not at all  □ 
 
6. Over the last week, how much have you  Very much  □ 
 avoided swimming or other sports because  Quite a lot  □ 
 of your skin trouble?     Only a little  □ 
Not at all  □ 
 
7. Last week,  If school time: Over  Prevented school □ 
was it  the last week, how  Very much  □ 
 school time?  much did your skin  Quite a lot  □ 
    problem affect your  Only a little  □ 
   OR   school work?   Not at all  □ 
 
 was it   If holiday time: How  Very much  □ 
 holiday time?  much over the last week, Quite a lot  □ 
has your skin problem Only a little  □ 
    interfered with your  Not at all  □ 
enjoyment of the holiday? 
 
 
8. Over the last week, how much trouble  Very much  □ 
 have you had because of your skin with  Quite a lot  □ 
 other people calling you names, teasing,  Only a little  □ 
 bullying, asking questions or avoiding you? Not at all  □ 
 
 
9. Over the last week, how much has your  Very much  □ 
 sleep been affected by your skin problem?  Quite a lot  □ 
Only a little  □ 




10. Over the last week, how much of a   Very much  □ 
 problem has the treatment for    Quite a lot  □ 
 skin been?      Only a little  □ 
Not at all  □ 
 
Please check that you have answered EVERY question. Thank you.  
M.S. Lewis-Jones, A.Y. Finlay, May 1993, This must not be copied without the 
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